Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ITOS - iTeos Therapeutics, Inc.
Market Cap 483.53M P/E 46.62 EPS this Y -26.30% Ern Qtrly Grth -
Income -108.14M Forward P/E -2.55 EPS next Y -47.00% 50D Avg Chg -5.00%
Sales 35M PEG - EPS past 5Y - 200D Avg Chg -20.00%
Dividend N/A Price/Book 0.74 EPS next 5Y - 52W High Chg -51.00%
Recommedations 1.70 Quick Ratio 17.70 Shares Outstanding 36.52M 52W Low Chg 8.00%
Insider Own 0.70% ROA -12.05% Shares Float 23.93M Beta 1.39
Inst Own 102.76% ROE -16.80% Shares Shorted/Prior 2.51M/2.50M Price 13.52
Gross Margin 100.00% Profit Margin - Avg. Volume 284,985 Target Price 34.50
Oper. Margin -37.92% Earnings Date Nov 5 Volume 250,232 Change -2.10%
Healthcare | Biotechnology | United States
About iTeos Therapeutics, Inc.

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

iTeos Therapeutics, Inc. News
11/15/24 iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
11/12/24 iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/24/24 iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
09/16/24 Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
09/15/24 ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC
09/14/24 TIGIT drug from iTeos shrinks lung tumors in trial
09/14/24 iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
08/28/24 iTeos to Participate in Upcoming Investor Conferences
08/25/24 We're Keeping An Eye On iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn Rate
08/20/24 iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
08/08/24 ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
08/08/24 iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
08/05/24 iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
07/09/24 iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial
07/08/24 iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
06/18/24 iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC
06/17/24 iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
06/05/24 Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package?
05/10/24 iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
05/10/24 iTeos Therapeutics Announces $120 Million Registered Direct Offering
ITOS Chatroom

User Image Night_Owl_Biotech Posted - 1 day ago

$STRO is off 40% the last 7 trading days. This is the largest drop of 25 peer clinical-stage oncology focused bios with market caps between $150 & $650MM (see attachment). STRO's enterprise value (market cap - cash) = -$167MM. STRO is running a potential reg'l trial in certain ovarian cancers not suited for Elahere & has engaged a banker (Lazard) to find a long-term partner. Put simplest, it is worth investors efforts to fully research STRO as, though of course STRO could fail, its risk/reward profile is compelling again (especially if you believe stocks like STRO trade in cycles) Other clinical-stage oncology focused bios trading for well less than cash with near-term pot'l value inflection points/data reads incl $CMPX $ITOS & $ZNTL $BDTX trades slightly higher than cash but expects a Phase 2 data read in certain lung cancers in Q125 (BDTX's therapy was deemed "de-risked" by Piper Sandler after an interim read 2 months ago). This is not investment advice.

User Image Allez Posted - 3 days ago

$ITOS someone in unloading

User Image NVDAMillionaire Posted - 3 days ago

$ITOS iTeos Therapeutics (ITOS): A Promising Biotech Navigating the Immuno-Oncology Landscape https://beyondspx.com/article/iteos-therapeutics-inc-nasdaq-itos-a-promising-immuno-oncology-player-advancing-novel-therapies

User Image AntBombman Posted - 6 days ago

$ITOS yeah GSK liked the phase 2 lung data that's why there is a phase 3 trial just started up. Ignore the doom mongers below.

User Image bullwink Posted - 1 week ago

$ITOS Is this the end? What is the end game?

User Image EZ904Duval Posted - 1 week ago

$ITOS If it doesn’t make cents, than it doesn’t make dollar

User Image Night_Owl_Biotech Posted - 10/27/24

Attached is $ITOS share price over the last 2 years. ITOS trades at a ~60% discount to 6/30/24 cash & A/R & has multiple data reads over the next 12 months. $STRO also trades for well less than cash while its Luvelta has near-term anticipated reads in ovarian cancer & NSCLC. $ZNTL is a 3rd with a large negative enterprise value. Azenosertib's clinical hold was just lifted. Data reads are expected in ovarian & USC by year end. This is not investment advice. All 3 are clinical-stage oncology focused bios which means it's very possible all 3 fail & investors incur 100% losses. Only 1 in 10 therapies in Phase 1 ever make it to market. However, 1 of the multiple data reads in any of the three could create meaningful value inflection points. Hence we only suggest investors follow these 3. We are unaware of any other credible clinical-stage oncology focused bios trading at such a large negative enterprise value. As always, do your own due diligence.

User Image InvestorNOR Posted - 10/22/24

$ITOS Strong support at $9!

User Image flytrader1 Posted - 1 month ago

$ITOS 10k put buyer $9 Jan25 for 50cent

User Image AntBombman Posted - 1 month ago

$ITOS interesting fall on news and rise much the same. A few buys today!

User Image ms0632 Posted - 1 month ago

$ITOS wonder how the investors that paid $17.50 in their direct offering are feeling now. This company needs to say something. Idiots.

User Image haupman Posted - 1 month ago

$ITOS gaps down every day. Supposedly huge cash balance.

User Image InvestorNOR Posted - 1 month ago

$ITOS Bleeding EVERY SINGLE DAY. Never seen that in my many years of trading on a company thats worth this much. Usually that happens on penny stocks

User Image haupman Posted - 1 month ago

$ITOS anyone consider the cash balance is fake? Nothing makes any sense here.

User Image haupman Posted - 1 month ago

$ITOS even at it's highs on the conference hype, this thing only traded right to its cash balance. Does the market think TGIT drugs are worthless?

User Image haupman Posted - 1 month ago

$ITOS what I like about this POS is that when it lifts 10 cents, the sellers get so offended, they rush in and push it right back down. They need to hit every bid.

User Image haupman Posted - 1 month ago

$ITOS another near-term hope is for Phase 2 data post the June cut off to be released soon.

User Image haupman Posted - 1 month ago

$ITOS seasonally weak time for biotechs but this one is literally the worst. It's just about at all time lows.

User Image InvestorNOR Posted - 1 month ago

$ITOS Just get whatever deal is possible. This company sucks at giving shareholders any value

User Image haupman Posted - 1 month ago

$ITOS there are no other biotechs that trade below cash balance, much less this far.

User Image InvestorNOR Posted - 1 month ago

$ITOS Absolutely crazy how this can go down so hard every single day

User Image haupman Posted - 1 month ago

$ITOS best thing for shareholders is for $GSK to cancel the drug development and return the rights back so the company can be liquidated.

User Image haupman Posted - 1 month ago

$ITOS bottom here is $0 folks.

User Image AntBombman Posted - 1 month ago

$ITOS $GSK are happy for the phase 2. They are funding a phase 3 off these results from ESMO. A little hint - you can only have a phase 3, if your phase 2 was positive. FDA wouldn't allow it otherwise...

User Image haupman Posted - 1 month ago

$ITOS it trades under 50% cash balance. No other stock does this. Something we are missing with this POS here.

User Image ms0632 Posted - 1 month ago

$ITOS this stock is in desperate need of a positive PR.

User Image InvestorNOR Posted - 1 month ago

$ITOS Remember folks, the news regarding the toxicity in the Phase 2 was because they included side effects from all cohorts. Including 1000mg. They chose 400mg for Phase 3, which should have a lot less side effects. And to add, all competitors that failed Phase 2 with Anti TIGIT did because they have to use high dose, but belrestotug have the advantage of not needing a high dose to beat existing anti cancer drugs on the market! Thats extremely bullish!

User Image InvestorNOR Posted - 1 month ago

$ITOS Everything is red today. What a great year this have been to be trading...

User Image haupman Posted - 1 month ago

$ITOS why has this stock spent so much time over the past few years trading below cash value? No other biotech does this.

User Image InvestorNOR Posted - 1 month ago

$ITOS https://www.biospace.com/drug-development/tigits-trend-upward-after-iteos-gsk-present-positive-data-at-esmo

Analyst Ratings
HC Wainwright & Co. Buy Sep 16, 24
Wells Fargo Overweight Aug 13, 24
JP Morgan Overweight Aug 12, 24
HC Wainwright & Co. Buy May 13, 24
JP Morgan Overweight Mar 12, 24
HC Wainwright & Co. Buy Mar 7, 24
JP Morgan Overweight Nov 13, 23
Wedbush Outperform Oct 18, 23
HC Wainwright & Co. Buy Aug 9, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Gall Matthew Chief Financial Offi.. Chief Financial Officer Oct 12 Buy 8.37 5,000 41,850 19,429 10/12/23
Boxer Capital, LLC Other Other Aug 23 Sell 15.56 350,000 5,446,000 1,804,058 08/25/23
Call Matthew Chief Operating Offi.. Chief Operating Officer Mar 28 Option 2.95 40,226 118,667 93,898 03/29/23
Hallal David Director Director Jun 08 Option 3.91 29,615 115,795 1,171 06/10/22
Hallal David Director Director Jun 08 Sell 20.04 29,615 593,485 06/10/22
Davis Aaron I. Director Director May 09 Sell 22.02 663,000 14,599,260 2,154,058 05/11/22
Davis Aaron I. Director Director Apr 28 Sell 27.41 375,000 10,278,750 2,817,058 05/02/22
Detheux Michel Chief Executive Offi.. Chief Executive Officer Apr 18 Option 4.23 11,500 48,645 37,763 04/19/22
Detheux Michel Chief Executive Offi.. Chief Executive Officer Apr 18 Sell 32.26 11,500 370,990 26,263 04/19/22
Davis Aaron I. Director Director Mar 22 Buy 32.81 50,000 1,640,500 3,192,058 03/24/22
Detheux Michel Chief Executive Offi.. Chief Executive Officer Mar 21 Sell 34.82 18,437 641,976 26,263 03/22/22
Boxer Capital, LLC 10% Owner 10% Owner Mar 17 Sell 35.25 575,201 20,275,835 3,142,058 03/18/22
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Mar 11 Option 4.3 3,500 15,050 3,500 03/14/22
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Mar 11 Sell 36.01 3,500 126,035 03/14/22
McGrath Yvonne Chief Scientific Off.. Chief Scientific Officer Mar 01 Option 4.24 10,000 42,400 10,000 03/02/22
McGrath Yvonne Chief Scientific Off.. Chief Scientific Officer Mar 01 Sell 36.76 10,000 367,600 03/02/22
Detheux Michel Chief Executive Offi.. Chief Executive Officer Feb 23 Sell 34.81 14,500 504,745 34,700 02/24/22
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Feb 11 Option 4.3 3,500 15,050 3,500 02/14/22
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Feb 11 Sell 35.9 3,500 125,650 02/14/22
Detheux Michel Chief Executive Offi.. Chief Executive Officer Jan 25 Sell 35.83 14,500 519,535 49,200 01/26/22
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Jan 14 Option 4.3 3,500 15,050 3,500 01/18/22
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Jan 14 Sell 39.42 3,500 137,970 01/18/22
Boxer Capital, LLC Director Director Jan 03 Sell 46.11 700,000 32,277,000 01/05/22
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Jan 03 Option 4.3 7,000 30,100 7,000 01/04/22
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Jan 03 Sell 51.9 7,000 363,300 01/04/22
Detheux Michel Chief Executive Offi.. Chief Executive Officer Dec 02 Option 4.3 30,000 129,000 79,863 12/22/21
Detheux Michel Chief Executive Offi.. Chief Executive Officer Dec 02 Sell 44.62 44,500 1,985,590 63,700 12/22/21
Hallal David Director Director Dec 20 Option 3.63 50,000 181,500 50,000 12/22/21
Hallal David Director Director Dec 20 Sell 43.57 50,000 2,178,500 12/22/21
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Dec 17 Option 4.3 7,000 30,100 7,000 12/17/21
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Dec 17 Sell 41 7,000 287,000 12/17/21
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Dec 10 Option 4.3 3,500 15,050 3,500 12/10/21
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Dec 10 Sell 34.5 3,500 120,750 12/10/21
MPM BIOVENTURES 2018, L.P. 10% Owner 10% Owner Dec 03 Sell 34.3 49,831 1,709,203 2,885,470 12/07/21
MPM BioVentures 2014, L.P. 10% Owner 10% Owner Dec 03 Sell 34.3 49,831 1,709,203 2,885,470 12/07/21
GADICKE ANSBERT 10% Owner 10% Owner Dec 03 Sell 34.3 83,390 2,860,277 4,730,197 12/07/21
MPM BIOVENTURES 2018, L.P. 10% Owner 10% Owner Nov 30 Sell 34.59 83,519 2,888,922 2,935,301 12/02/21
MPM BioVentures 2014, L.P. 10% Owner 10% Owner Nov 30 Sell 34.59 83,519 2,888,922 2,935,301 12/02/21
GADICKE ANSBERT 10% Owner 10% Owner Nov 30 Sell 34.59 139,773 4,834,748 4,813,587 12/02/21
MPM BIOVENTURES 2018, L.P. 10% Owner 10% Owner Nov 26 Sell 35.34 23,045 814,410 3,018,820 11/30/21
MPM BioVentures 2014, L.P. 10% Owner 10% Owner Nov 26 Sell 35.34 23,045 814,410 3,018,820 11/30/21
GADICKE ANSBERT 10% Owner 10% Owner Nov 26 Sell 35.34 38,566 1,362,922 4,953,360 11/30/21
Detheux Michel Chief Executive Offi.. Chief Executive Officer Nov 22 Option 12.45 16,263 202,474 92,700 11/24/21
Detheux Michel Chief Executive Offi.. Chief Executive Officer Nov 22 Sell 36.08 14,500 523,160 78,200 11/24/21
GADICKE ANSBERT 10% Owner 10% Owner Nov 17 Sell 36.56 129,617 4,738,798 4,991,926 11/24/21
MPM BIOVENTURES 2018, L.P. 10% Owner 10% Owner Nov 17 Sell 36.56 77,455 2,831,755 3,041,865 11/24/21
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Nov 18 Option 4.3 28,000 120,400 28,000 11/19/21
Lager Joanne Jenkins Chief Medical Office.. Chief Medical Officer Nov 18 Sell 34.5 28,000 966,000 11/19/21
Detheux Michel Chief Executive Offi.. Chief Executive Officer Oct 15 Sell 28.01 1,836 51,426 97,190 10/19/21
MPM BIOVENTURES 2018, L.P. 10% Owner 10% Owner Oct 15 Sell 27.56 17,099 471,248 3,134,991 10/18/21